Table 2: Comparison clinical characteristics between participants with and without sarcopenia.
|
Variable |
Overall (n = 235) |
Non-Sarcopenia (n = 179) |
Sarcopenia (n = 56) |
P value* |
|
Diabetes Duration (years) |
19.04 ± 8.25 |
18.20 ± 7.95 |
21.75 ± 8.65 |
0.005 |
|
HbA1c (%) |
7.46 ± 1.22 |
7.45 ± 1.27 |
7.52 ± 1.04 |
0.699 |
|
MUST Score No malnutrition |
221 (94%) |
172 (96.1%) |
49 (87.5%) |
|
|
Risk of malnutrition |
14 (6%) |
7 (3.9%) |
7 (12.5%) |
0.018 |
|
Biochemistry |
||||
|
LDL-C (mg/dl) |
80.94 ± 32.70 |
81.03 ± 33.64 |
80.68 ± 29.82 |
0.945 |
|
HDL-C (mg/dl) |
51.99 ± 12.78 |
51.55 ± 12.18 |
53.41 ± 14.77 |
0.346 |
|
Total Cholesterol (mg/dl) |
156.61 ± 40.02 |
156.32 ± 40.47 |
157.54 ± 38.87 |
0.843 |
|
Triglycerides (mg/dl) |
112 (83.0-148.5) |
112 (83.0-147.5) |
116 (86.5-152.5) |
0.959 |
|
Creatinine Urine |
65.9 (39.95-99.05) |
67.3 (41.95-102.05) |
51.45 (32.1-83.25) |
0.038 |
|
Microalbumin/Creatinine ratio |
12 (5.95-31.6) |
11.3 (5.7-27.25) |
16.8 (5.95-42.9) |
0.316 |
|
Vitamin D (ng/mL) |
40.64 ± 12.82 |
39.43 ± 13.20 |
44.49 ± 10.72 |
0.010 |
|
Diabetes Complications/Comorbidities |
||||
|
Retinopathy Absence of Retinopathy |
168 (71.5%) |
126 (70.4%) |
42 (75.0%) |
|
|
Presence of Retinopathy |
67 (28.5%) |
53 (29.6%) |
14 (25.0%) |
0.505 |
|
Neuropathy Absence of Neuropathy |
201 (85.5%) |
156 (87.2%) |
45 (80.4%) |
|
|
Presence of Neuropathy |
34 (14.5%) |
23 (12.8%) |
11 (19.6%) |
0.207 |
|
Nephropathy Absence of Nephropathy |
198 (84.3%) |
151 (84.4%) |
47 (83.9%) |
|
|
Presence of Nephropathy |
37 (15.7%) |
28 (15.6%) |
9(16.1%) |
0.939 |
|
Urine Albumin Normoalbuminuria |
178 (76.4%) |
136 (76.8%) |
42 (75.0%) |
|
|
Microalbuminuria |
52 (22.3%) |
38 (21.5%) |
14 (25.0%) |
|
|
Macroalbuminuria |
3 (1.3%) |
3 (1.7%) |
0 (0.0%) |
0.547 |
|
Hypertension Absence of hypertension |
69 (29.4%) |
51 (28.5%) |
18 (32.1%) |
|
|
Presence of hypertension |
166 (70.6%) |
128 (71.5%) |
38 (67.9%) |
0.601 |
|
Dyslipidemia Absence of dyslipidemia |
6 (2.6%) |
6 (3.4%) |
0 (0.0%) |
|
|
Presence of dyslipidemia |
229 (97.4%) |
173 (96.6%) |
56 (100.0%) |
0.165 |
|
CVD Absence of CVD |
216 (91.9%) |
163 (91.1%) |
53 (94.6%) |
|
|
Presence of CVD |
19 (8.1%) |
16 (8.9%) |
3 (5.4%) |
0.391 |
|
Glucose-lowering therapies |
||||
|
GLP-1 Not taking |
128 (54.5%) |
94 (52.5%) |
34 (60.7%) |
|
|
Taking |
107 (45.5%) |
85 (47.5%) |
22 (39.3%) |
0.282 |
|
Insulin Not taking |
168 (71.5%) |
124 (69.3%) |
44 (78.6%) |
|
|
Taking |
67 (28.5%) |
55 (30.7%) |
12 (21.4%) |
0.179 |
|
Bariatric Surgery No |
231 (98.3%) |
175 (97.8%) |
56 (100.0%) |
|
|
Yes |
4 (1.7%) |
4 (2.2%) |
0 (0.0%) |
0.259 |
|
Sulfonylureas Not taking |
141 (60.0%) |
115 (64.2%) |
26 (46.4%) |
|
|
Taking |
94 (40.0%) |
64 (35.8%) |
30 (53.6%) |
0.018 |
|
Biguanides Not taking |
22 (9.4%) |
17 (9.5%) |
5 (8.9%) |
|
|
Taking |
213 (90.6%) |
162 (90.5%) |
51 (91.1%) |
0.899 |
|
TZD Not taking |
216 (92.3%) |
168 (93.9%) |
48 (87.3%) |
|
|
Taking |
18 (7.7%) |
11 (6.1%) |
7 (12.7%) |
0.109 |
|
SGLT-2 Not taking |
33 (14.0%) |
26 (14.5%) |
7 (12.5%) |
|
|
Taking |
202 (86.0%) |
153 (85.5%) |
49 (87.5%) |
0.703 |
|
Meglitinides Not taking |
225 (95.7%) |
173 (96.6%) |
52 (92.9%) |
|
|
Taking |
10 (4.3%) |
6 (3.4%) |
4 (7.1%) |
0.220 |
|
DPP4 Not taking |
149 (63.4%) |
118 (65.9%) |
31 (55.4%) |
|
|
Taking |
86 (36.6%) |
61 (34.1%) |
25 (44.6%) |
0.152 |
|
AGIs Not taking |
231 (98.3%) |
176 (98.3%) |
55 (98.2%) |
|
|
Taking |
4 (1.7%) |
3 (1.7%) |
1 (1.8%) |
0.956 |
*Chi-square analysis was carried out for the categorical variables (presented as number and percentage). Continuous variables with non-normal distribution are presented as median (interquartile range) and analyzed using the Mann-Whitney U test, while normally distributed continuous variables are presented as mean ± standard deviation and compared using independent samples t-tests. P value was significant at p < 0.05.